Date of Event: November 05, 2026 (specific time not mentioned)
Purpose: Discussion of Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026
Recording Availability: The audio recording has been made available on the company's investor relations website at https://www.molbiodiagnostics.com/investors/
Regulatory Compliance: This disclosure is made pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Management Participants: Not specified in this disclosure
UPSI Statement: The document does not contain any specific statement regarding unpublished price sensitive information
Additional Notes Section
Financial Data: No financial figures or performance metrics are disclosed in this announcement
Attachments: No attachments are mentioned in this specific disclosure
Follow-up: This letter is in continuation to the company's previous communication dated November 02, 2026
